Robert M Samstein, MD, PhD
img_Robert M Samstein
ASSISTANT PROFESSOR | Radiation Oncology
ASSISTANT PROFESSOR | Immunology & Immunotherapy
Are you a patient?
Specialties
Radiation Oncology
Research Topics
Anti-Tumor Therapy, Autoimmunity, Biomedical Sciences, Breast Cancer, Cancer, Cancer Genetics, Cellular Immunity, Clinical Genomics, DNA Recombination, DNA Repair, Genetics, Genomics, Immunology, Mucosal Immunology, Oncogenes, Personalized Medicine, Pharmacogenomics, T Cells, Translational Research, Tumor Suppressor Genes, Tumorigenesis
Multi-Disciplinary Training Area
Cancer Biology [CAB], Immunology [IMM]
Dr. Samstein’s research interests are focused on understanding the interaction between the patient’s immune system and cancer cells in the tumor, elucidating the role of the DNA damage repair and response pathway in altering the tumor’s ability to be recognized and attacked by the immune system. His laboratory will work to identify new strategies to harness the immune anti-tumor response and expand the therapeutic window of traditional immunotherapies.

Visit the Samstein Laboratory

MD, Weill Medical College of Cornell University

MD, Weill Cornell Medical College

PhD, Weill Cornell / Sloan Kettering / Rockefeller Tri-I MD-PhD Program

Memorial Sloan Kettering Cancer Center

Internship, Transitional Year, Memorial Sloan-Kettering Cancer Center

Residency, Radiation Oncology, Memorial Sloan-Kettering Cancer Center

Certifications

Radiation Oncology

2020

Solomon Silver Award in Clinical Medicine

2020

American Association of Immunologists Pfizer-Showell Award

2019

Burrough Wellcome Career Award for Medical Scientists

2019

RSNA Roentgen Reseach Award

2018

AACR Translational Immunology Award

2017

American Board of Radiology Holman Research Pathway

Publications

Selected Publications

Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial(Nature Medicine, 10.1038/s41591-023-02568-1). Matthew D. Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G. Chan, Sara Lewis, Bassam El Achkar, Tanya B. Dorff, Jeremy Paul Cetnar, Brock O. Neil, Anishka D’Souza, Ronac Mamtani, Christos Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir Horowitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, Diane M. Del Valle, G. Kenneth Haines, Li Wang, Kent W. Mouw, Robert M. Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim-Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John Sfakianos, Sumanta K. Pal. Nature Medicine

Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery. Claudia I. Henschke, Rowena Yip, Qi Sun, Pengfei Li, Andrew Kaufman, Robert Samstein, Cliff Connery, Leslie Kohman, Paul Lee, Henry Tannous, David F. Yankelevitz, Emanuela Taioli, Kenneth Rosenzweig, Raja M. Flores, Raja Flores, Dong Seok Lee, Daniel Nicastri, Andrea Wolf, Kimberly Song, Jorge Gomez, Pinaki Dutta, Mary Beth Beasley, Maureen Zakowski, Michael Chung, Rebecca Schwartz, Huiwen Chan, Jeffrey Zhu, Sydney Kantor, Sydney Woode, Ardeshir Hakami, Arzu Buyuk, Adie Friedman, Ronald Dreifuss, Stacey Verzosa, Mariya Yakubox, Karina Aloferdova, Patricia Stacey, Simone De Nobrega, Lauren Lentini, Harvey Pass, Benjamin Cooper, Andre Moreirea, Audrey Sorensen, Robert Dunton, Jason Wallen, Christopher Curtiss, Cliff P. Connery, Artit Jirapatnakul, Robert Korst, Mary Salvatore. Journal of Thoracic Oncology

An immunogenetic basis for lung cancer risk. Chirag Krishna, Anniina Tervi, Miriam Saffern, Eric A. Wilson, Seong Keun Yoo, Nina Mars, Vladimir Roudko, Byuri Angela Cho, Samuel Edward Jones, Natalie Vaninov, Myvizhi Esai Selvan, Zeynep H. Gümüş, FinnGen, Tobias L. Lenz, Miriam Merad, Paolo Boffetta, Francisco Martínez-Jiménez, Hanna M. Ollila, Robert M. Samstein, Diego Chowell. Science

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Samstein during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • International Association for the Study of Lung Cancer

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.